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 INTRODUCING CONTRACEPTIVE METHODS  
IN LOW-RESOURCE SETTINGS:  
NEW OPPORTUNITIES IN NIGERIA   
 
 
Three-Month Progesterone Vaginal Ring  
The three-month PVR, a user-initiated 
contraceptive, can be used safely by postpartum 
breastfeeding women to help space pregnancies. 
The ring contains natural progesterone and does 
not affect a woman’s ability to produce breast 
milk. Each ring can be used continuously for three 
months, and four rings can be used successively 
the first year after childbirth. Fertility generally returns shortly 
after discontinuation. The PVR is approved in eight Latin 
American countries, and efforts are underway to introduce it  
in more countries where contraceptive choices during 
breastfeeding are limited and where prolonged lactation is 
prevalent.  
 
One-Year NES/EE Contraceptive Vaginal Ring  
The one-year NES/EE CVR is a long-acting 
contraceptive in the late stages of development. It 
contains Nestorone® (NES), a new progestin that 
has been shown to be effective in suppressing 
ovulation, and ethinyl estradiol (EE), an approved, 
marketed hormonal compound. Once inserted by 
the woman, the NES/EE CVR is designed to be left in place for 
three weeks, removed for one week to allow for a monthly 
menstrual cycle, and then reinserted by the woman. The same 
ring can be used for up to 13 cycles (one year), with the goal of 
minimizing product cost and time spent visiting a provider or 
pharmacist. Phase 3 clinical trials have been completed, as 
have additional clinical and product specification studies 
required by the FDA. The Population Council is preparing a New 
Drug Application to submit to the FDA for regulatory review. 
 
 
 
PROJECT DESCRIPTION  
In October 2013, USAID awarded the Delivering 
Contraceptive Vaginal Rings project to the Population 
Council to foster the introduction of two contraceptive 
methods. The objectives of this project are to:  
1) improve availability and affordability of a three-
month Progesterone Vaginal Ring (PVR) for 
postpartum breastfeeding women, and  
2) facilitate regulatory approval and introduction of a 
one-year contraceptive vaginal ring containing 
Nestorone® and ethinyl estradiol (NES®/EE)—a 
long-acting method for non-breastfeeding women 
that is in the late stages of development. 
MILESTONES ACHIEVED   
 
 
 
 
Continued progress was made in preparing 
the New Drug Application for the 
investigational NES®/EE CVR for submission 
to the US Food & Drug Administration (FDA).
Findings from Acceptability and Willingness 
to Pay studies were widely disseminated
at national and global levels.
The PVR has been added to the World
Health Organization’s Expression of 
Interest (EOI) following inclusion in
WHO’s MEC and EML. 
Project partner WomanCare Global (WCG) 
began compilation of the PVR dossier in 
preparation for registration with Nigeria’s 
regulatory body, the National Agency for Food 
and Drug Administration and Control 
(NAFDAC).
WCG also identified a Market 
Authorization Holder (MAH) for the PVR 
to ensure compliance with relevant 
regulatory requirements, post-
registration.
 
 
     
 
 
 
YEAR 4 ACTIVITIES 
(OCTOBER 2016 – SEPTEMBER 2017) 
 
2.1  Implementation research on product introduction 
No activities proposed. 
 
2.2  Register the PVR in Kenya, Malawi, Nigeria, 
Senegal, and Zambia 
Project partner WomanCare Global (WCG) will: 
 
 
2.3  Technical assistance for WHO Pre-Qualification of 
the PVR 
• Project staff continue to provide technical assistance to 
PVR manufacturer Grünenthal in many thematic areas 
including a PK study, stability testing, and validation of 
analytical methods. Grünenthal will seek WHO-PQ to  
 
Complete registration with 
the Nigerian regulatory body 
and continue on the pathway 
toward country registration in 
Kenya and Senegal.
Work closely with the 
selected MAH, which will be 
responsible for 
pharmacovigilance of the 
PVR post-registration.
Conduct a regulatory audit of 
the PVR manufacturing plant, 
a requirement of regulators 
and national ministries of 
health.
facilitate PVR procurement by a wider number of agencies 
including UNFPA, USAID, ministries of health, and social 
marketing organizations. 
• Results of a clinical trial conducted by the Population Council 
in India in collaboration with the Indian Council of Medical 
Research comparing the safety and efficacy of the PVR 
versus the IUD will be finalized for inclusion in the WHO-PQ 
application. 
• Project staff will continue analysis of used PVRs and 
compare with data collected from acceptability studies in 
each country. The secondary analysis will reveal the extent to 
which women adhere to PVR use; results will inform 
refinement of user instructions, including those related to 
ring disposal. 
 
2.4  Design introductory strategies for contraceptive 
vaginal rings 
 
Foster 
partnerships 
with a wide 
range of 
stakeholders, 
implementing 
partners, USAID-
funded projects, 
private sector 
social marketing 
organizations, 
professional 
associations, 
and reproductive 
supply networks 
to support 
subsequent 
introduction of 
vaginal rings.
Advocate for 
inclusion of 
vaginal rings in 
national EMLs, 
and identify 
policy and 
program 
opportunities for 
integrating new 
contraceptives 
into existing 
implementation 
plans, providing 
a unified 
platform for 
introduction 
planning.
Convene 
meetings to 
develop 
strategies to 
introduce vaginal 
rings, with an 
emphasis on 
identifying and 
training provider 
cadres from 
multiple 
distribution 
channels within 
the private and 
public sectors. 
KEY PROJECT CONTACTS 
The Population Council will lead the proposed project activities, along with a consortium that includes WomanCare Global, 
Grünenthal, and QPharma. For more information about the products or the Delivering Contraceptive Vaginal Rings project, 
contact Dr. Sylvia Adebajo, Dr. John Townsend, or the USAID/Washington project management staff. 
Population Council staff leading this effort in Nigeria: 
• Dr. Sylvia Adebajo (sadebajo@popcouncil.org) 
• Dr. Salisu Ishaku 
US-based Population Council staff directing the project:  
• Dr. John Townsend, Principal Director (jtownsend@popcouncil.org) 
• Dr. Saumya RamaRao  
• Dr. Ruth Merkatz  
Office of Population and Reproductive Health, USAID/Washington project management staff: 
• Dr. Judy Manning, Agreement Officer’s Representative (jmanning@usaid.gov) 
• Ms. Tabitha Sripipatana, Technical Advisor (tsripipatana@usaid.gov) 
• Mr. Clifton Kenon, Technical Advisor (ckenon@usaid.gov) 
 
 
